CSL stock biotechnology group at EUR 121.91 pre-market
Published on 10/23/2026 at 08:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDates and business ahead
- CSL develops plasma products, vaccines and therapies for serious diseases.
- CSL's 2026 annual general meeting is scheduled for October 27, 2026.
- CSL stock trades pre-market at EUR 121.91 at 8:49 a.m. CEST at Lang & Schwarz on October 23, 2026.
CSL develops and sells plasma products, vaccines and therapies for serious diseases. The stock trades pre-market at EUR 121.91 at 8:49 a.m. CEST at Lang & Schwarz on October 23, 2026.
Ahead of the Xetra open
The pre-market price is based on Lang & Schwarz trading in Germany before the Xetra session. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of CSL stock.
Business and the upcoming AGM
CSL operates through CSL Behring, CSL Seqirus and CSL Vifor, with activities spanning plasma products, influenza vaccines, pandemic services, iron deficiency and nephrology, according to the company's investor-relations information. CSL's 2026 annual general meeting is scheduled for October 27, 2026, in Melbourne and online, the company said on its investor page. Shareholders may attend at Sofitel Melbourne on Collins or participate online. Market context: Market report S&P/ASX 200.
